Clicky

Rigel Pharmaceuticals, Inc.(RIGL)

Description: Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.


Keywords: Cancer Chemical Compounds Autoimmune Disease Rheumatoid Arthritis Drug Development Asthma Phosphates Enzymes Ophthalmic Tyrosine Kinase Cancer Cell Lupus Adenosine Tyrosine Kinase Inhibitors Protein Kinase Syk Daiichi Sankyo Inflammatory And Autoimmune Diseases Janus Kinase Tyrosine Kinases Discoid Lupus Erythema Muscle Disorders Portola Pharmaceuticals

Home Page: www.rigel.com

RIGL Technical Analysis

1180 Veterans Boulevard
South San Francisco, CA 94080
United States
Phone: 650 624 1100


Officers

Name Title
Mr. Raul R. Rodriguez Pres, CEO & Director
Mr. Dean L. Schorno CPA Exec. VP & CFO
Dr. Wolfgang Dummer M.D., Ph.D. Exec. VP & Chief Medical Officer
Mr. David A. Santos Exec. VP & Chief Commercial Officer
Mr. Joseph Lasaga Exec. VP of Corp. Devel.
Ms. Julie Patel Sr. VP of HR
Dr. Esteban S. Masuda Exec. VP of Research
Mr. Tarek Sallam VP of Marketing

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 31.6366
Price-to-Sales TTM: 2.5561
IPO Date: 2000-11-29
Fiscal Year End: December
Full Time Employees: 165
Back to stocks